Haleon approves key resolutions at 2025 AGM

UK – Haleon plc, a global leader in consumer health, has announced the results of its 2025 Annual General Meeting (AGM), where all proposed resolutions were approved.

Shareholders passed resolutions 1 through 18 as ordinary resolutions, while resolutions 19 to 22 were approved as special resolutions.

The vote, conducted via poll, showed strong shareholder engagement, with over 83% of issued share capital participating in most decisions.

Major resolutions included the re-election of board members, approval of the Directors’ Remuneration Report, declaration of a final dividend, and the reappointment of KPMG as auditors.

Shareholders also approved key authorizations, including political donations, share buybacks, allotment of ordinary shares, and disapplication of pre-emption rights. A 14-day notice period for general meetings was also authorized.

These approvals reflect confidence in Haleon’s leadership and long-term strategy. The company, known for trusted consumer health brands such as Sensodyne, Panadol, Voltaren, Centrum, and Advil, continues to focus on improving everyday health through science and innovation.

In line with its financial strategy, Haleon also announced the purchase and cancellation of 820,380 ordinary shares as part of its ongoing share buyback program.

This move reduces the total number of voting shares to 9,011,009,299 and aims to strengthen shareholder value by optimizing the capital structure.

Full details of the AGM resolutions are available on Haleon’s website and the UK’s National Storage Mechanism.